此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Microneedling-Assisted Hyaluronic Acid for Interdental Papilla Deficiency

2026年11月1日 更新者:Hisham Hussein、Badr University

Microneedling-Assisted Hyaluronic Acid for Interdental Papilla Deficiency: Effects on Gingival Crevicular Fluid Biomarkers and Clinical Outcomes-A Randomized Controlled Clinical Trial

This randomized controlled clinical trial will evaluate whether microneedling combined with cross-linked hyaluronic acid injection provides superior reconstruction of interdental papilla deficiency compared with hyaluronic acid injection alone. Twenty participants with Nordland-Tarnow Class I or II interdental papilla deficiency will be randomly allocated into two parallel groups. The test group will receive microneedling followed by submucosal injection of cross-linked hyaluronic acid, while the control group will receive cross-linked hyaluronic acid injection alone. Three treatment sessions will be performed at 4-week intervals. Participants will be followed for 6 months. The primary outcome will be change in black triangle height. Secondary outcomes will include gingival crevicular fluid levels of MMP-9, TIMP-1 and periostin, plaque index, gingival index, periodontal probing depth, and patient satisfaction.

研究概览

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Young adult patients aged .
  • Presence of at least one interdental papilla defect classified as Nordland-Tarnow Class I or II.
  • Distance between the contact point and the interproximal bone crest ≤7 mm.
  • No open contact between the affected teeth.
  • Full-mouth periodontal treatment completed prior to enrollment.
  • Willingness to participate and ability to provide written informed consent.

Exclusion Criteria:

  • Systemic conditions affecting wound healing, soft tissue turnover, or immune response, including uncontrolled diabetes mellitus, immunosuppression, or coagulation disorders.
  • Current use of anticoagulants, systemic corticosteroids, bisphosphonates, or medications known to affect gingival tissue or bone metabolism.
  • Known hypersensitivity or allergy to hyaluronic acid or any component of the injectable preparation.
  • Pregnancy or breastfeeding.
  • Active periodontal disease.
  • Nordland-Tarnow Class III papilla loss at the study site.
  • Previous soft tissue augmentation procedures, surgical or injectable, at the study site.
  • Use of any local or systemic anti-inflammatory medication within 3 months before enrollment.
  • Smokers.
  • Presence of restorations, crowns, veneers, or orthodontic brackets at or adjacent to the study site.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Microneedling + Hyaluronic Acid (MN+HA)

Participants will receive microneedling of the interdental papilla followed by submucosal injection of cross-linked hyaluronic acid. Three treatment sessions will be performed at 4-week intervals.

A sterile disposable microneedling device will be applied to the interdental papilla using controlled vertical and oblique strokes until uniform punctate bleeding is observed.

Cross-linked hyaluronic acid will be administered by submucosal injection into the interdental papilla. Three treatment sessions will be performed at 4-week intervals.

有源比较器:Hyaluronic Acid (HA)

Participants will receive submucosal injection of cross-linked hyaluronic acid without preceding microneedling. Three treatment sessions will be performed at 4-week intervals.

Cross-linked hyaluronic acid will be administered by submucosal injection into the interdental papilla. Three treatment sessions will be performed at 4-week intervals.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Black Triangle Height
大体时间:Baseline, 1 month, 3 months, and 6 months

Black triangle height will be measured in millimeters as the linear distance from the base of the interproximal contact point to the most coronal tip of the interdental papilla using a calibrated UNC-15 periodontal probe. Standardized acrylic stents will be used to ensure reproducible probe angulation and reference point positioning.

Baseline, 1 month, 3 months, and 6 months

次要结果测量

结果测量
措施说明
大体时间
Gingival Crevicular Fluid Periostin Level
大体时间:Baseline, 1 month, 3 months, and 6 months

Periostin concentration in gingival crevicular fluid will be measured using a commercially available human periostin ELISA kit.

Baseline, 1 month, 3 months, and 6 months
Gingival Crevicular Fluid MMP-9 Level
大体时间:Baseline, 1 month, 3 months, and 6 months

MMP-9 concentration in gingival crevicular fluid will be measured using a commercially available human MMP-9 ELISA kit.

Baseline, 1 month, 3 months, and 6 months
Gingival Crevicular Fluid TIMP-1 Level
大体时间:Baseline, 1 month, 3 months, and 6 months

TIMP-1 concentration in gingival crevicular fluid will be measured using a commercially available human TIMP-1 ELISA kit.

Baseline, 1 month, 3 months, and 6 months
Plaque Index
大体时间:Baseline, 1 month, 3 months, and 6 months

Plaque accumulation will be assessed using the Silness and Löe Plaque Index on a score from 0 to 3.

Baseline, 1 month, 3 months, and 6 months
Gingival Index
大体时间:Baseline, 1 month, 3 months, and 6 months

Gingival inflammation will be assessed using the Löe and Silness Gingival Index on a score from 0 to 3.

Baseline, 1 month, 3 months, and 6 months
Periodontal Probing Depth
大体时间:Baseline, 1 month, 3 months, and 6 months

Periodontal probing depth will be measured in millimeters from the gingival margin to the base of the sulcus or periodontal pocket using a UNC-15 periodontal probe.

Baseline, 1 month, 3 months, and 6 months
Patient Satisfaction
大体时间:6 months

Patient satisfaction with esthetic appearance will be assessed using a visual analogue scale at the end of the follow-up period.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年5月1日

研究注册日期

首次提交

2026年11月1日

首先提交符合 QC 标准的

2026年11月1日

首次发布 (实际的)

2026年11月5日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月1日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • BUC-IACUC-260517-185

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅